• Bionano Genomics Inc BNGO.OQ BNGO.O is expected to show a fall in quarterly revenue when it reports results on March 3 (estimated) for the period ending December 31 2024

• The San Diego California-based company is expected to report a 42.2% decrease in revenue to $6.2 million from $10.72 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company's guidance on January 13 2025, for the period ended December 31, was for revenue between $7.90 million and $8.10 million.

• ​LSEG's mean analyst estimate for Bionano Genomics Inc is for a loss of $6.00 per share.

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Bionano Genomics Inc is $60.00​, above​ its last closing price of $4.38. ​​​

This summary was machine generated February 28 at 21:30 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)